April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Subjective And Objective Measures Of Glare After Laser Peripheral Iridectomy Randomized To One Eye: the ZAP Trial
Author Affiliations & Notes
  • Nathan G. Congdon
    Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Mingguang He
    Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Paul Foster
    Moorfields, London, United Kingdom
  • Yuzhen Jiang
    Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Jian Zhang
    Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Xixi Yan
    Preventive Ophthalmology, Zhongshan Ophthalmic Center, Guangzhou, China
  • Tom van den Berg
    Neth. Inst. Neuroscience, Amsterdam, The Netherlands
  • David Friedman
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Nathan G. Congdon, Alcon Laboratories (R); Mingguang He, None; Paul Foster, None; Yuzhen Jiang, None; Jian Zhang, None; Xixi Yan, None; Tom van den Berg, Royal Academy (P); David Friedman, None
  • Footnotes
    Support  Fight for Sight (UK) and Sun Yat Sen University 5010 Project Fund
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5020. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nathan G. Congdon, Mingguang He, Paul Foster, Yuzhen Jiang, Jian Zhang, Xixi Yan, Tom van den Berg, David Friedman; Subjective And Objective Measures Of Glare After Laser Peripheral Iridectomy Randomized To One Eye: the ZAP Trial. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5020.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To understand which aspects of the size and location of a laser peripheral iridotomy (LPI) are associated with objectively-measured straylight scatter and subjective glare.

Methods: : A convenience sample of subjects from the ZAP trial, who had received LPI at random in one eye for narrow angles 18 months previously, underwent the following: vision assessment, photo-documentation of LPI with photogrammetry (vertical/horizontal diameter, circumference, area, clock hour, distance from limbus and pupil, covered/uncovered/partially covered by lid in primary and downward gaze), bilateral LOCS III cataract grading, and ocular straylight testing (C-Quant, Oculus, Inc., Lynnwood WA). Subjects were also asked about subjective glare using two questions from the NEI VFQOL questionnaire.

Results: : Among 134 subjects, mean age was 60.6 +/- 5.13 years, 80.6% were women, 61.9% had presenting VA ≥ 20/25, 20.1% had nuclear opalescence > 3.0, 16.4% had cortical cataract > 2.5, none had any PSC, 10.4% (n=14) reported subjective glare, and 10.4% (n=14) and 14.2% (n=19) had LPI partially and totally uncovered by the lid in primary gaze respectively. Straylight score in the treated and un-treated eyes did not differ for all subjects (P = 0.5) or for subjects with partially/totally un-covered LPI (P = 0.6). In univariate and multivariate analyses, only worse cortical cataract grade (P < 0.001), and not LPI size or location, was significantly associated with straylight score. Only older age (P = 0.03), and not any of the LPI size/ location parameters, was significantly associated with subjective glare in multivariate models.

Conclusions: : The impact of even un-covered LPI on objective measures of straylight does not appear to be great compared to that of lens opacity. Initial results suggest that programs to screen and treat narrow angles may be unlikely to result in significant glare disability. Recruitment of subjects is on-going, and objective/subjective glare data for age- and gender-matched un-treated controls will be reported.

Clinical Trial: : www.controlled-trials.com, ISRCTN45213099

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • anterior chamber 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×